Travere Therapeutics price target lowered to $27 from $31 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on Travere Therapeutics (TVTX) to $27 from $31 and keeps a Buy rating on the shares ...
piratemedia1.com3d
Students of ECU's School of Dental Medicine hosted oral cancer 5k this past Saturday
East Carolina University’s Student National Dental Association hosted its 5th oral cancer 5k on March 29th to raise money for patients needing emergency dental procedures.
Scotiabank Remains a Hold on Apellis Pharmaceuticals (APLS)
Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases
Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.
Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...
Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.